Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Latest Biotechnology and Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc. Stock News

As of May 7, 2026, Catalyst Pharmaceuticals, Inc. had a $3.8 billion market capitalization, compared to the Biotechnology median of $275.8 million. Catalyst Pharmaceuticals, Inc.’s stock is up 33.6% in 2026, up 8.5% in the previous five trading days and up 35.15% in the past year.

Currently, Catalyst Pharmaceuticals, Inc.’s price-earnings ratio is 18.6. Catalyst Pharmaceuticals, Inc.’s trailing 12-month revenue is $589.0 million with a 36.4% net profit margin. Year-over-year quarterly sales growth most recently was 7.6%. Analysts expect adjusted earnings to reach $2.859 per share for the current fiscal year. Catalyst Pharmaceuticals, Inc. does not currently pay a dividend.

As of May 7, 2026, Syndax Pharmaceuticals, Inc. had a $1.8 billion market cap, putting it in the 53rd percentile of all stocks. Syndax Pharmaceuticals, Inc.’s stock is down 0.9% in 2026, up 8.8% in the previous five trading days and up 93.05% in the past year.

Currently, Syndax Pharmaceuticals, Inc. does not have a price-earnings ratio. Syndax Pharmaceuticals, Inc.’s trailing 12-month revenue is $217.2 million with a -112.0% net profit margin. Year-over-year quarterly sales growth most recently was 224.5%. Analysts expect adjusted earnings to reach $-1.746 per share for the current fiscal year. Syndax Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Catalyst Pharmaceuticals, Inc.	CPRX	D
Syndax Pharmaceuticals, Inc.	SNDX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Catalyst Pharmaceuticals, Inc. has a Value Score of 37, which is Expensive. Syndax Pharmaceuticals, Inc. has a Value Score of 6, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals or Inc. is the better investment when it comes to value.

Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Catalyst Pharmaceuticals, Inc.	CPRX	B
Syndax Pharmaceuticals, Inc.	SNDX	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Catalyst Pharmaceuticals, Inc. has a Quality Score of 77, which is Strong. Syndax Pharmaceuticals, Inc. has a Quality Score of 6, which is Very Weak.

The Quality Grade Winner: Catalyst Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Catalyst Pharmaceuticals, Inc. has a better overall quality grade than Syndax Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Catalyst Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Catalyst Pharmaceuticals, Inc.	CPRX	B
Syndax Pharmaceuticals, Inc.	SNDX	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Catalyst Pharmaceuticals, Inc. has a Momentum Score of 73, which is Strong. Syndax Pharmaceuticals, Inc. has a Momentum Score of 79, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. have a grade of B. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals or Inc. Stock?

Overall, Catalyst Pharmaceuticals, Inc. stock has a Value Score of 37, Momentum Score of 73 and Quality Score of 77.

Syndax Pharmaceuticals, Inc. stock has a Value Score of 6, Momentum Score of 79 and Quality Score of 6.

Comparing Catalyst Pharmaceuticals, Inc., Syndax Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.